Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAKTS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAktis Oncology Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 09, 2026
āļāļĩāļāļĩāđāļRoden (Matthew)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ117
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJan 09
āļāļĩāđāļāļĒāļđāđ17 Drydock Avenue
āđāļĄāļ·āļāļBOSTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02210
āđāļāļĢāļĻāļąāļāļāđ13026587581
āđāļ§āđāļāđāļāļāđhttps://www.aktisoncology.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAKTS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 09, 2026
āļāļĩāļāļĩāđāļRoden (Matthew)
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Ms. Jill K. Frizzley
Independent Director
Mr. Matthew R. Kahn, CPA
Independent Director
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Mr. Kyle D. Kuvalanka
Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Ms. Jill K. Frizzley
Independent Director
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ